AbbVie Inc. (NYSE: ABBV), the global biopharmaceutical company headquartered in North Chicago, announced on February 23, 2026, a major $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago campus. This move represents a significant expansion of domestic pharmaceutical production and aligns with AbbVie’s broader strategy of strengthening U.S. manufacturing capacity while supporting next-generation medicines for neurological
